Real-World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study.

At week 16, higher baseline Severity of Alopecia Tool reduced the odds of response (β = -0.061, SE 0.029; p = 0.034).

Response was lower in universalis (unadjusted p = 0.008).

Adverse events occurred in 16 of 46 patients (34.8%), mostly mild, with two patients (4.3%) discontinuing treatment.

A second JAKi was used in seven patients (15.2%): Three complete, two partial, and two absent responses occurred post-switch.